ChemoCentryx Inc (OQ:CCXI)

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: 850 Maude Ave
Tel: 1-650-2102900
IR: See website
Key People
Thomas J. Schall
Chairman of the Board, President, Chief Executive Officer
Susan M. Kanaya
Chief Financial Officer, Executive Vice President, Chief Administrative Officer, Secretary
Markus J. Cappel
Chief Business Officer, Treasurer
Business Overview
ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).
Financial Overview
For the three months ended 31 March 2020, ChemoCentryx Inc revenues decreased 28% to $6M. Net loss increased 81% to $21.7M. Revenues reflect Collaboration and license revenue from r decrease of 30% to $5.9M. Higher net loss reflects Research and development increase of 26% to $19.3M (expense), General and administrative increase of 60% to $8.8M (expense), Interest income decrease of 12% to $984K (income).
Employees: 82 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $3,630M as of Mar 31, 2020
Annual revenue (TTM): $33.81M as of Mar 31, 2020
EBITDA (TTM): -$66.49M as of Mar 31, 2020
Net annual income (TTM): -$65.23M as of Mar 31, 2020
Free cash flow (TTM): -$80.90M as of Mar 31, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 66,992,661 as of Jun 10, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization